Dimension Therapeutics Inc (NASDAQ:DMTX) was downgraded by investment analysts at Citigroup Inc from a “buy” rating to a “neutral” rating in a report issued on Friday, May 12th. They presently have a $1.50 price objective on the biotechnology company’s stock. Citigroup Inc’s price target would suggest a potential upside of 25.00% from the company’s previous close.
DMTX has been the topic of a number of other reports. Zacks Investment Research downgraded Dimension Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Jefferies Group LLC restated a “buy” rating and set a $7.00 price target on shares of Dimension Therapeutics in a research note on Thursday, February 2nd. Canaccord Genuity set a $20.00 price target on shares of Dimension Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, January 31st. Finally, Cantor Fitzgerald cut shares of Dimension Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $32.00 to $3.00 in a research note on Tuesday, January 31st. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $7.21.
Dimension Therapeutics (DMTX) opened at 1.20 on Friday. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $10.47. The stock’s 50 day moving average price is $1.33 and its 200 day moving average price is $2.62. The firm’s market capitalization is $30.05 million.
Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.02. Dimension Therapeutics had a negative return on equity of 50.07% and a negative net margin of 464.39%. The firm had revenue of $3.62 million for the quarter. On average, equities analysts expect that Dimension Therapeutics will post ($1.75) EPS for the current year. Several institutional investors have recently made changes to their positions in the stock. Turner Investments LLC bought a new position in shares of Dimension Therapeutics during the fourth quarter worth $131,000. Renaissance Technologies LLC bought a new position in shares of Dimension Therapeutics during the fourth quarter worth $236,000. Two Sigma Securities LLC bought a new position in shares of Dimension Therapeutics during the first quarter worth $108,000. Geode Capital Management LLC raised its position in shares of Dimension Therapeutics by 7.3% in the first quarter. Geode Capital Management LLC now owns 145,896 shares of the biotechnology company’s stock worth $255,000 after buying an additional 9,946 shares during the last quarter. Finally, State Street Corp raised its position in shares of Dimension Therapeutics by 37.2% in the fourth quarter. State Street Corp now owns 186,544 shares of the biotechnology company’s stock worth $812,000 after buying an additional 50,570 shares during the last quarter. 85.43% of the stock is owned by institutional investors.
Receive News & Ratings for Dimension Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Dimension Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.